

## TANZANIA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Tanzania						
<b>2. Grant number:</b> 17-TZA-12c-X / 1820-TZA-12d-X						
<b>3. Date of Decision Letter:</b> 16 December 2016						
<b>4. Date of the Partnership Framework Agreement:</b> 01 July 2013						
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine						
<b>6. Vaccine type:</b> Pneumococcal						
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID, Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID <sup>1</sup>						
<b>8. Programme duration<sup>2</sup>:</b> 2012 - 2020						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2012-2016	2017	2018	2019	2020	Total <sup>3</sup>
Programme Budget (US\$)	\$117,757,267 <sup>4</sup>	\$23,733,500	\$21,107,500	\$22,605,000	\$24,068,500	\$209,271,767
<b>10. Vaccine introduction grant:</b> Not Applicable						
<b>11. Indicative Annual Amounts:</b>						
Type of supplies to be purchased with Gavi funds in each year		2012-2016	2017			
Number of Pneumococcal vaccines doses			6,321,800			
Annual Amounts (US\$)		US\$117,757,267 <sup>5</sup>		US\$23,733,500		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>13. Self-procurement:</b> Not applicable						

<sup>1</sup> Country requested a switch to PCV13, 4 dose vial, in 2017. The timing of the first shipments of PCV13, 4 dose vial, will be determined during the development of the 2017 shipment plan based on your desired timing, the stock of the existing presentation of PCV, supply availability, and programmatic readiness to switch. Wastage has been estimated at 10% to align with WHO indicative wastage for the PCV13 4 dose vial and co-financing is aligned with your desired presentation in anticipation of the switch.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:** Reference code: 17-TZA-12c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	388,300	416,200	428,600	433,200
Value of vaccine doses (US\$)	US\$1,281,093			
Total co-financing payments (US\$) (including freight)	US\$1,342,500	US\$1,311,000	US\$1,350,000	US\$1,386,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
16 December 2016